SCHEMBL27010669

SCHEMBL27010669

CC(C)N(C)C1CCCCC1N(C)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 3/20 0.63
SIGMAR1 Q99720 1/20 0.43
HRH4 Q9H3N8 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
EBP Q15125 1/20 0.41
OPRK1 P41145 3/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 1/20 0.41
TSHR P16473 2/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LTA4H P09960 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27010694 0.85 SLC18A3 (0.46) SLC18A3SIGMAR1HRH4HRH3LTA4H
SCHEMBL11463073 0.83 SLC18A3 (0.71) SLC18A3SIGMAR1HRH4HRH3OPRK1
SCHEMBL27010700 0.83 KDM4E (0.52) SLC18A3OPRK1OPRM1TSHRL3MBTL1
SCHEMBL11464581 0.80 SLC18A3 (0.66) SLC18A3SIGMAR1HRH4HRH3OPRK1
SCHEMBL27010674 0.79 SLC18A3 (0.60) SLC18A3SIGMAR1HRH4HRH3EBP
SCHEMBL27010666 0.79 SMN1; SMN2 (0.41) SLC18A3HRH3OPRK1OPRM1OPRD1
SCHEMBL11748732 0.78 SLC18A3 (0.67) SLC18A3SIGMAR1HRH4HRH3OPRK1
SCHEMBL6391373 0.78 SLC18A3 (1.00) SLC18A3SIGMAR1HRH4HRH3EBP
SCHEMBL6391371 0.78 SLC18A3 (1.00) SLC18A3SIGMAR1HRH4HRH3EBP
SCHEMBL9433040 0.78 SLC18A3 (1.00) SLC18A3SIGMAR1HRH4HRH3EBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 SLC18A3 1846/4885SIGMAR1 3709/4885HRH4 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.